Active immunotherapy for chronic diseases

Vaccine

Volumn 31, Issue 14, 2013, Pages 1777-1784

  Bachmann, Martin F ^a,b   Whitehead, Piers ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Neovacs SA   (France)

Author keywords

Immunotherapy; Monoclonal antibody; Vaccine

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CERTOLIZUMAB PEGOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ALLERGIC ASTHMA; ALZHEIMER DISEASE; BREAST CANCER; CACHEXIA; CHRONIC DISEASE; CONTRACEPTION; CROHN DISEASE; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS CANCER; PASSIVE IMMUNIZATION; PATIENT COMPLIANCE; PRIMARY TREATMENT FAILURE; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY TREATMENT FAILURE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 84875253322     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.001     Document Type: Review

References (66)

1. La Merie. Top 30 Biologics 2011. La Merie R&D Pipeline News; 2012.
2. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
3. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
4. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
5. Chaparro M., Panes J., Garcia V., Merino O., Nos P., Domenech E., et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012, 18:685-690.
6. Hetland M.L., Christensen I.J., Tarp U., Dreyer L., Hansen A., Hansen I.T., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
7. Barrera P., Joosten L.A., den Broeder A.A., van de Putte L.B., van Riel P.L., van den Berg W.B. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:660-669.
8. Montero-Julian F.A., Klein B., Gautherot E., Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995, 85:917-924.
9. Hyrich K.L., Symmons D.P., Watson K.D., Silman A.J. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:1786-1794.
10. Du Pan S.M., Dehler S., Ciurea A., Ziswiler H.R., Gabay C., Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61:560-568.
11. Finckh A., Simard J.F., Gabay C., Guerne P.A. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006, 65:746-752.
12. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
13. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
14. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.O., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
15. Carmona L., Gomez-Reino J.J. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8:R72.
16. Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
17. Bultman E., de Haar C., van Liere-Baron A., Verhoog H., West R.L., Kuipers E.J., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012, 35:335-341.
18. Cordero Ruiz P., Castro Marquez C., Mendez Rufian V., Castro Laria L., Caunedo Alvarez A., Romero Vazquez J., et al. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig 2011, 103:294-298.
19. Baert F., Glorieus E., Reenaers C., D'Haens G., Peeters H., Franchimont D., et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2012, 7:154-160.
20. Bartelds G.M., Wolbink G.J., Stapel S., Aarden L., Lems W.F., Dijkmans B.A., et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006, 65:1249-1250.
21. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
22. Stakeholder Insight Rheumatoid arthritis - Rising competition by line and severity. Datamonitor DMHC 2592; 2010.
23. Pascual-Salcedo D., Plasencia D., Ramiro S., Nun L., Bonilla G., Nagore D., et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011, 50:1445-1456.
24. Ducourau E., Mulleman D., Paintaud G., Miow Lin D.C., Lauféron F., Ternant D., et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13:R105.
25. Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
26. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
27. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
28. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
29. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
30. Dryden G.W. Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther 2009, 9:967-974.
31. Lowe D., Dudgeon K., Rouet R., Schofield P., Jermutus L., Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011, 84:41-61.
32. the World Health Report: 2003: shaping the future. http://www.who.int/whr/2003/en/whr03_en.pdf.
33. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288:462-467.
34. NCEP EP Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
35. Ansell J.E. Emerging therapies in anticoagulation. Manag Care 2004, 13:8-12.
36. Medication Digest. Compliance-Adherence-Persistence. American Pharmacists Association and Pfizer Inc; 2003.
37. IMS Health. IMS special strategy supplement, ; 2008. http://www.imshealth.com/deployedfiles/ims/Global/Content/Innovation/Powering%20Client%20Transformation/Portfolio%20Strategy/InVivoArticle.pdf.
38. Billioud V., Laharie D., Filippi J., Roblin X., Oussalah A., Chevaux J.B., et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011, 17:152-159.
39. Kane S.V., Chao J., Mulani P.M. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009, 26:936-946.
40. Borah B.J., Huang X., Zarotsky V., Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009, 25:1365-1377.
41. http://clinicaltrials.gov/ct2/show/nct00647270.
42. Market and product forecasts: disease modification in rheumatoid arthritis - novel therapies plus reformulations poised to enter the market. Datamonitor, September 2011, HC00080-002.
43. National Institute Health Clinical Excellence (NICE). TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: audit support. NICE guidance; 2010.
44. National Institute Health Clinical Excellence (NICE). Systemic lupus erythematosus (active) - belimumab: final appraisal determination. NICE guidance; 2012.
45. Vermasvuori R., Koskinen J., Salonen K., Siren N., Weegar J., Dahlbacka J., et al. Production of recombinant HIV-1 nef protein using different expression host systems: a techno-economical comparison. Biotechnol Prog 2009, 25:95-102.
46. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1:443-452.
47. http://www.sec.gov/Archives/edgar/data/1551152/000104746912006434/a2209760zex-99_1.htm.
48. Human Genome Sciences Credit Suisse investor call. http://www.hgsi.com/benlysta-belimumab-3.html.
49. Simoens S., Verbeken G., Huys I. Biosimilars and market access: a question of comparability and costs?. Target Oncol 2012, 7:227-231.
50. National Collaborating Centre for Chronic Conditions U Rheumatoid arthritis: national clinical guideline for management and treatment in adults. NICE clinical guidelines, No. 79 2009, Royal College of Physicians, London, UK.
51. CNS Market Access in China - investment in mental health. Datamonitor; 2011.
52. Oberg K., Alm G. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 1997, 10:1-5.
53. Zagury D., Le Buanec H., Mathian A., Larcier P., Burnett R., Amoura Z., et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U.S.A. 2009, 106(13 (March)):5294-5299.
54. Kisand K., Link M., Wolff A.S., Meager A., Tserel L., Org T., et al. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008, 112:2657-2666.
55. Houssiau F.A., Rashkov R., Hachulla E., Lazaro E., Jorgensen C., Spertini F., et al. Active immunization against IFN with IFN-Kinoid in SLE patients is safe, immunogenic and induces down-regulation of IFN mediated genes. Arthritis Rheum 2011, 60:S963.
56. Spohn G., Keller I., Beck M., Grest P., Jennings G.T., Bachmann M.F. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 2008, 38:877-887.
57. Elliott W.J. The economic impact of hypertension. J Clin Hypertens 2003, 5:3-13.
58. Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000, 5(Suppl. 1):S31-S34.
59. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
60. Brown M.J., Coltart J., Gunewardena K., Ritter J.M., Auton T.R., Glover J.F. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107:167-173.
61. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63-72.
62. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821-827.
63. Bachmann M.F., Dyer M. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nature Rev Drug Discov 2004, 3:81-88.
64. Talwar G.P., Singh O., Pal R., Chatterjee N., Sahai P., Dhall K., et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci U.S.A. 1994, 91:8532-8536.
65. Burmester G.R., Panaccione R., Gordon K.B., McIlraith M.J., Lacerda A.P. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012, 10.1136/annrheumdis-2011-201244.
66. St Clair E.W., Wagner C.L., Fasanmade A.A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.